189 related articles for article (PubMed ID: 8575125)
1. Dialysate CA125 in stable CAPD patients: no relation with transport parameters.
Pannekeet MM; Koomen GC; Struijk DG; Krediet RT
Clin Nephrol; 1995 Oct; 44(4):248-54. PubMed ID: 8575125
[TBL] [Abstract][Full Text] [Related]
2. The effect of dwell time on dialysate cancer antigen 125 appearance rates in patients on continuous ambulatory peritoneal dialysis.
Akman S; van Westrhenen R; De Waart DR; Hiralall JK; Zweers MM; Krediet RT
Adv Perit Dial; 2003; 19():24-7. PubMed ID: 14763029
[TBL] [Abstract][Full Text] [Related]
3. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
4. Dialysate cancer antigen 125 levels in children treated with peritoneal dialysis.
Bouts AH; Groothoff JW; van Amstel SP; Zweers MM; Davin JC; Krediet RT
Adv Perit Dial; 2000; 16():328-31. PubMed ID: 11045322
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of changes in serum and dialysate levels of cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients.
Passadakis P; Panagoutsos S; Thodis E; Tsivara I; Sopassi F; Kartali S; Vargemezis V
Adv Perit Dial; 1999; 15():40-4. PubMed ID: 10682070
[TBL] [Abstract][Full Text] [Related]
6. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients.
Visser CE; Brouwer-Steenbergen JJ; Betjes MG; Koomen GC; Beelen RH; Krediet RT
Nephrol Dial Transplant; 1995; 10(1):64-9. PubMed ID: 7724031
[TBL] [Abstract][Full Text] [Related]
7. Dialysate cell population and cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients: their relationship with transport parameters.
Lai KN; Lai KB; Szeto CC; Ho KK; Poon P; Lam CW; Leung JC
Am J Kidney Dis; 1997 May; 29(5):699-705. PubMed ID: 9159303
[TBL] [Abstract][Full Text] [Related]
8. Influence of dialysis duration, peritoneal transport parameters, and gender on effluent CA125 concentration in patients on peritoneal dialysis.
Mojahedi MJ; Hami M; Shakeri MT; Hekmat R
Iran J Kidney Dis; 2007 Oct; 1(2):78-81. PubMed ID: 19363281
[TBL] [Abstract][Full Text] [Related]
9. Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis.
Ho-dac-Pannekeet MM; Hiralall JK; Struijk DG; Krediet RT
Adv Perit Dial; 1997; 13():17-22. PubMed ID: 9360644
[TBL] [Abstract][Full Text] [Related]
10. Effect of amino acid based dialysate on peritoneal blood flow and permeability in stable CAPD patients: a potential role for nitric oxide?
Douma CE; de Waart DR; Struijk DG; Krediet RT
Clin Nephrol; 1996 May; 45(5):295-302. PubMed ID: 8738660
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor, and interleukin-6: relationship with peritoneal transport.
Rodrigues A; Martins M; Santos MJ; Fonseca I; Oliveira JC; Cabrita A; Melo e Castro J; Krediet RT
Adv Perit Dial; 2004; 20():8-12. PubMed ID: 15384786
[TBL] [Abstract][Full Text] [Related]
12. The relationship between peritoneal transport characteristics and messenger RNA expression of aquaporin in the peritoneal dialysis effluent of CAPD patients.
Szeto CC; Lai KB; Chow KM; Szeto CY; Li PK
J Nephrol; 2005; 18(2):197-203. PubMed ID: 15931648
[TBL] [Abstract][Full Text] [Related]
13. Differences in fluid and solute transport between diabetic and nondiabetic patients at the onset of CAPD.
Serlie MJ; Struijk DG; de Blok K; Krediet RT
Adv Perit Dial; 1997; 13():29-32. PubMed ID: 9360646
[TBL] [Abstract][Full Text] [Related]
14. Peritoneal transport characteristics with glycerol-based dialysate in peritoneal dialysis.
Smit W; de Waart DR; Struijk DG; Krediet RT
Perit Dial Int; 2000; 20(5):557-65. PubMed ID: 11117247
[TBL] [Abstract][Full Text] [Related]
15. Influence of pH-neutral peritoneal dialysis solution.
Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N
Adv Perit Dial; 2002; 18():68-71. PubMed ID: 12402590
[TBL] [Abstract][Full Text] [Related]
16. Peritoneal kinetics of cancer antigen 125 in peritoneal dialysis patients: the relationship with peritoneal outcome.
Jiménez C; Díaz C; Selgas R; Auxiliadora Bajo M; del Peso G; Sánchez-Tomero JA; Gonzalez-Gancedo P
Adv Perit Dial; 1999; 15():36-9. PubMed ID: 10682069
[TBL] [Abstract][Full Text] [Related]
17. Necessity of correcting cancer antigen 125 appearance rates by body surface area.
Kawanishi H; Moriishi M; Harada Y; Sakikubo E; Nagai T; Tsuchiya S
Adv Perit Dial; 2000; 16():22-5. PubMed ID: 11045255
[TBL] [Abstract][Full Text] [Related]
18. Dialysate CA125 levels in children on continuous peritoneal dialysis.
Turhan P; Sever L; Caliskan S; Kasapcopur O; Sever A; Hacibekiroglu M; Arisoy N
Pediatr Nephrol; 2005 Nov; 20(11):1615-21. PubMed ID: 16133054
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of peritoneal membrane integrity.
Krediet RT
J Nephrol; 1997; 10(5):238-44. PubMed ID: 9364314
[TBL] [Abstract][Full Text] [Related]
20. Outcome for continuous ambulatory peritoneal dialysis patients is not predicted by peritoneal permeability characteristics.
Passadakis PS; Thodis ED; Panagoutsos SA; Selisiou CA; Pitta EM; Vargemezis VA
Adv Perit Dial; 2000; 16():2-6. PubMed ID: 11045251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
